Abstract library

47 results for "Chinese".
#2850 A Clinical Controlled Observation of Chinese Herbal Decoction (SMLJ01) for Type 1 Gastric Neuroendocrine Neoplasms
Introduction: Type 1 gastric neuroendocrine neoplasms (g-NENs) usually have good prognosis, however, most patients(pts) experience the recurrence after endoscopic resection.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Prof. Huang-Ying Tan
Authors: Chen Y Y, Han D, Zhu J Q, Chen J, ...
#2914 Safety Profile and Adverse Events of Special Interest for Surufatinib in Chinese Patients with Advanced Extra-Pancreatic Neuroendocrine Tumors: Analysis of the Phase 3 SANET-ep Trial
Introduction: The previously reported SANET-ep trial (NCT02588170) demonstrated surufatinib significantly improves progression-free survival (PFS) in patients (pts) with advanced extrapancreatic neuroendocrine tumors (epNETs) compared to placebo; median PFS (9.2 vs. 3.8 months; HR = 0.334, 95% CI 0.223 to 0.499, p
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Jie Li
Authors: Li J, Xu J, Zhou Z, Bai C, ...
#2857 Clinical Epidemiology Study of Rectal Neuroendocrine Neoplasms in China: A National Multicenter 10-Year Retrospective Study
Introduction: Representative data on the rectal neuroendocrine neoplasms in Chinese patients is rare.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: professor Fan Jinhu
Authors: Jinhu F, Yihebali C, Huan Y, Su Z, ...
#2876 Efficacy of Surufatinib in Western Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNETs)
Introduction: Surufatinib is a targeted inhibitor of tyrosine kinases VEGFR1, 2, & 3, FGFR1, and CSF-1R. The safety profile was favorable in 2 completed studies (NCT02133157, NCT02267967) conducted in China. A recent phase 3 placebo controlled study (NCT02588170) confirmed safety, and demonstrated superior efficacy (PFS: 9.2 v 3.8 months) of Surufatinib in Chinese pts with advanced extra-pancreatic NETs (epNET).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Medical Writer Kimberly Louis
Authors: Dasari A, Paulson S, Sung M, Tucci C, ...
#2949 Sunitinib May Be an Effective Treatment for Hypercalcemia Due To a Metastatic Pancreatic Neuroendocrine Tumor
Introduction: Malignant hypercalcemia due to neuroendocrine tumor(NET) is rare, and only a few reports are available in the literature.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Prof. Huang-Ying Tan
Authors: Wang C, Qi Z, Tan H D, Tan H Y, ...
#599 Rectal Neuroendocrine Tumors: Long-Term Survival After Resection and Prognostic Factors
Introduction: The rectum is the third most common location for gastrointestinal carcinoids after small bowel and colon. Due to their rarity, the characteristics and behavior of this unusual malignancy remain unclear.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Cai Jianqiang
Authors: Du F, Chi Y H B L, Zhao H, Wang J W, ...
#609 Clinicopathological Analysis in 119 Cases of Rectal Neuroendocrine Tumors
Introduction: The new diagnostic criteria of the WHO 2010 Neuroendocrine Tumour Classification are not understood and applied in China.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Pathology, grading, staging
Presenting Author: Professor Po Zhao
Authors: Meng M, Zhao P, ...
#611 GEP-NET in 2012 from Chinese People’s Libration Army General Hospital
Introduction: WHO 2010 GEP-NET Classification without the traditional terms as carcinoid and atypical carcinoid is not well-accepted in China.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Pathology, grading, staging
Presenting Author: Professor Po Zhao
Authors: Zhao P, Meng M, ...
#663 Comparing Chinese Pancreatic Neuroendocrine Tumors with Americans: Their Clinicopathological Features and Prognosis
Introduction: It is unknown if clin-patho features of PNET pts are different between China and USA, the largest country in the east and west, respectively.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Biomarkers
Presenting Author: Dr. X.W. Qiao
Authors: Qiao X W, Tang L, Zhu L M, Chen J, ...
#727 Serum Levels of Chromogranin A Were Not Elevated in Patients with Insulinomas
Introduction: According to ENETS and NANETS Consensus Guidelines, Chromogranin A (CgA) is the most practical and useful serum tumor marker in NET patients (pts), including pancreatic NETs. Many studies suggested that test of blood CgA should be mandatory for NET diagnosis.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr. X-W Qiao
Authors: Qiao X W, Qiu L, Liu B, Song Y L, ...